{
  "id": 20930521,
  "title": "1 antibody neutralizes all 3 pathogenic human coronaviruses",
  "url": "https://urgent.news/2026/11/20/1-antibody-neutralizes-all-3-pathogenic-human-coronaviruses",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-20T18:03:35.000Z",
  "source": {
    "name": "Futurity",
    "slug": "futurity",
    "url": "https://www.futurity.org/antibody-neutralizes-coronaviruses-3353822/"
  },
  "original_language": "en",
  "account": "A groundbreaking therapeutic antibody has been developed by researchers that effectively neutralizes all three highly pathogenic human coronaviruses – SARS-CoV, SARS-CoV-2, and MERS-CoV. This significant discovery comes amidst ongoing infections and potential new outbreaks of these viruses. Led by the Institute for Biomedical Sciences at Georgia State University, the study involved researchers from multiple American institutions.\n\nNanobodies, tiny antibody fragments, were identified and selected for their strong binding affinity and cost-effective production. These nanobodies, specifically 3B11 against SARS-CoV and SARS-CoV-2, and 1C11 against MERS-CoV, bound to the receptor-binding domains (RBDs) of these viruses. The RBDs are crucial parts of the viral spike proteins that facilitate cell entry.\n\nNanobody 3B11 neutralized diverse SARS-CoV and SARS-CoV-2 strains, while 1C11 effectively neutralized all tested MERS-CoV strains. When combined with the Fc segment of a human antibody, the potency of 1C11 significantly increased. These nanobodies work by obstructing the interaction between viral RBDs and their corresponding human cell receptors.\n\nInvestigations using cryo-electron microscopy, computational modeling, and epitope-mapping revealed the unique sites on the viral proteins recognized by the nanobodies, providing insights into their mechanism of action. A bispecific nanobody, 3B11−1C11-Fc, was created to target all three RBDs simultaneously. This bispecific nanobody remained stable under various pH and temperature conditions, and could be produced in large quantities at high yield in mammalian cells, ensuring potential scalability for widespread use.\n\nIn mouse models, a single dose of this bispecific nanobody significantly decreased viral loads and protected the animals from infections caused by SARS-CoV, SARS-CoV-2, and MERS-CoV, without causing severe side effects. The lead researcher, Distinguished University Professor Lanying Du, expressed optimism about this bispecific nanobody's potential for further therapeutic development, highlighting its promise in combating these highly pathogenic coronaviruses. The study, funded by the National Institute of Allergy and Infectious Diseases and the National Institute of General Medical Sciences of the National Institutes of Health, was published in the journal ACS Nano.",
  "summary": "\"Our goal was to develop a single therapeutic that could address all three highly pathogenic coronaviruses.\"",
  "key_points": [
    "Researchers develop antibody neutralizing SARS-CoV, SARS-CoV-2, and MERS-CoV",
    "Nanobodies 3B11, 1C11, and 3B11−1C11-Fc target viral receptor-binding domains",
    "Mouse studies show single dose reduces viral loads and protects against infections"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}